A Pilot Study to Increase Take-up of Overdose Reversal Drugs

How to cite

Jacobson, Mireille; Powell, David. 2020. "A Pilot Study to Increase Take-up of Overdose Reversal Drugs." AEA RCT Registry. AEARCTR-0005333. https://doi.org/10.1257/rct.5333-2.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Mireille Jacobson* , David Powell

* Primary investigator

Registry ID
AEARCTR-0005333
DOI
https://doi.org/10.1257/rct.5333-2.0
First registered
Last updated
Status
In development
Trial dates
2020-04-23 – 2021-06-30
Countries
Private
JEL codes
I1. Health
Registry record
http://www.socialscienceregistry.org/trials/5333

Abstract

Despite widespread public attention to the opioid epidemic and numerous policies to prevent opioid misuse, overdose deaths in the United States increased 16 percent per annum between 2014 and 2017. Public health authorities consider naloxone, a prescription opioid-overdose reversal drug, a key strategy to stemming the tide of overdose deaths and recommend dispensing the medication along with high-dose opioid prescriptions. Nonetheless, naloxone take-up remains low. In collaboration with an online pharmacy platform licensed to dispense naloxone in many states, we will use an online advertising campaign to pilot test approaches to increasing naloxone purchases. Randomizing advertisements across counties, we will measure how traffic to the pharmacy site and naloxone purchases respond to purchase price and information content, including how salient the ads make stigma. We will also consider the impact of advertising more generally. This pilot will be used to scale up to a study that sheds light on both the price elasticity of demand for naloxone and potential non-price barriers to take-up.

Intervention

In partnership with an online naloxone distributor, we will test the importance of price and information (including stigma) in deterring access to naloxone. More specifically, we will implement randomized experiments (via Google Ads) for multiple concurrent interventions related to price, and information. We will monitor ad exposure (or impressions), clicks or traffic driven to the exchange site by different types of advertisements, and subsequent purchases. Google Analytics will also be used to track clicks and purchases made from counties that are randomized to receive no ads.

Experimental design

We will run concurrent experiments through the Google Adwords platform to randomize ads that address information gaps and/or stigma issues that may be barriers to the take-up of naloxone. We exclude counties in which the online naloxone distributor is not selling naloxone (as of March 31, 2020).

Randomization will occur at the county level. We will also randomly allocate counties to a control arm that receives no advertising from us. Across our treatment conditions, we will further randomize the advertised (and thereby offered) price of naloxone. In the end, we have 5 approximately equally-sized groups of counties.

Using 2018 overdose data, we constructed the opioid overdose rate for each county as well as indicators for each quintile of the opioid overdose distribution. To improve balance on these metrics, we re-randomized until all 5 experimental arms were within 0.5 opioid overdoses per 100,000 of each other and the distributions were similar as well (for each quintile, no arm is more than 10 percentage points larger than any other arm).

Design details

Randomization method
In office by computer
Randomization unit
county
Clusters
2354 counties
Observations
4500 clicks
Arms
1500 clicks per treatment condition
Primary outcomes
naloxone doses purchases
Secondary outcomes
ad impressions; ad clicks; website visits; revenue

Cited by

No citation data available for this registration yet.

Keywords